CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, named its new Board of Directors led by co-founder Jérôme Koch, in line with recent bridge financing organized ...
Berlin (ots) - Der Frühling steht vor der Tür, doch die aktuelle Grippewelle hat Deutschland weiterhin fest im Griff. In der ...
Arvinas and Pfizer’s targeted protein degrader has not managed to distinguish itself from other, similar breast cancer drugs, according to pivotal data re ...
Pfizer and Arvinas’ estrogen receptor (ER) degrader has failed a key part of its first phase 3 test, although the companies have pointed to success in a subpopulation to suggest the therapy ...
A UK startup that wants to bring protein degraders to the neurodegeneration field has closed a $31 million seed round.
DUESSELDORF, Germany (Reuters) -A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna. In a statement, the court in the city of ...
DUESSELDORF, Germany, March 5 (Reuters) - A German court on Wednesday ruled that Pfizer (PFE.N), opens new tab and its partner BioNTech (22UAy.DE), opens new tab violated a COVID-19 vaccine patent ...
Pfizer CEO Albert Bourla said his company is ready to shift its manufacturing operations into the U.S. should the need arise. He made the comments at the 45th TD Cowen Annual Health Care Conference in ...
As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert Bourla, Ph.D., outlined one potential response by his company if ...
Pfizer (PFE) CEO Albert Bourla said on Monday that the drugmaker could move some of its overseas manufacturing to its U.S. plants if necessary, as the Trump administration considers imposing ...
March 3 (Reuters) - Pfizer (PFE.N), opens new tab CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the United States, if required ...
Pfizer (NYSE:PFE) has made significant updates to its diversity, equity, and inclusion (DEI) webpage, becoming the latest Big Pharma after GSK (NYSE:GSK) to revise DEI initiatives amid the Trump ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback